Skip to main content

Table 1 Baseline clinical characteristics and biochemical assessments of plaque progression study

From: Chromosome 9p21.3 polymorphism in a Chinese Han population is associated with angiographic coronary plaque progression in non-diabetic but not in type 2 diabetic patients

  CAD
  Plaque Progression
(n = 137)
No Plaque Progression
(n = 293)
P
Men/Female (n) 97/40 208/85 0.864
Age (years) 64.13 ± 7.80 65.51 ± 10.13 0.299
Cigarette smoking (%) 61(44.5%) 139(47.4%) 0.604
Hypertension (%) 65 (47.4%) 130 (44.4%) 0.512
Hyperlipidemia (%) 36 (26.3%) 65 (22.1%) 0.466
Diabetes (%) 69 (43.0%) 81 (28.0%) 0.033
BMI (kg/m2) 24.63 ± 3.46 24.05 ± 3.24 0.189
Fasting plasma glucose (mmol/L) 5.49 ± 1.88 5.99 ± 2.00 0.255
2 h plasma glucose (mmol/L) 13.40 ± 4.20 11.29 ± 3.66 0.039
HbA1c (%) 6.79 ± 1.48 6.64 ± 1.43 0.315
hsCRP (mg/ml) 19.35 ± 13.63 11.87 ± 9.22 <0.001
Total cholesterol (mmol/L) 4.77 ± 1.04 4.84 ± 1.16 0.631
Triglyceride (mmol/L) 1.93 ± 1.53 2.02 ± 1.32 0.319
LDL-C (mmol/L) 2.80 ± 0.79 2.84 ± 0.85 0.672
HDL-C (mmol/L) 1.09 ± 0.31 1.27 ± 0.27 0.015
apoA (g/L) 1.22 ± 0.20 1.27 ± 0.22 0.156
apoB (g/L) 0.97 ± 0.22 0.95 ± 0.23 0.674
Lipoprotein (a) (g/L) 0.25 ± 0.18 0.23 ± 0.16 0.422
BUN (mmol/L) 5.49 ± 1.89 5.88 ± 1.65 0.078
creatinine (mg/L) 91.51 ± 23.16 89.78 ± 20.08 0.534
Statin (%) 126 (92.1%) 262 (89.5%) 0.475
ACEI or ARB (%) 114 (83.3%) 231 (79.0%) 0.285
β-blocker (%) 59 (43.1%) 121 (50.9%) 0.448
Antiplatelet (%) 123 (90.1%) 215 (90.3%) 0.656
Insulin (%) 36 (26.2%) 30 (12.7%) 0.069
Oral anti-diabetic drugs (%) 49 (35.7%) 111 (46.5%) 0.144
  1. Data are number (%) and mean ± SD;
  2. Abbreviations: CAD, coronary artery disease; BMI, body mass index; HbA1c, glycosylated hemoglobin; hsCRP, high sensitivity C-reactive protein; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; BUN, blood urea nitrogen.